SEC Form 4 · accession 0001193125-26-389892
Definium Therapeutics, Inc. · DFTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Karlin
Officer — Chief Medical Officer
Period of report
Sep 14, 2026
Accepted (ET)
Sep 14, 2026 · 8:30 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001813814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Sep 14, 2026 | A | 200,000 | $0.00 | A | 803,699 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
- F2Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.